EHD4 Antibody

What is EHD4 and what are its key molecular characteristics?

EHD4, also known as PAST4 or EH domain-containing protein 4, belongs to the EHD protein family that regulates endocytic recycling pathways. It is a 61 kDa protein (observed molecular weight) consisting of 541 amino acids in humans . EHD4 contains an EH domain critical for protein-protein interactions in membrane trafficking. The protein is encoded by the EHD4 gene (Gene ID: 30844) and exhibits high homology with other EHD family members (EHD1-3), presenting challenges for developing specific antibodies . In cellular contexts, EHD4 primarily localizes to early endosomes where it regulates endocytic trafficking of various cargoes .

What are the recommended applications for EHD4 antibodies?

EHD4 antibodies have been validated for multiple applications with specific recommended dilutions:

When using these antibodies, it is recommended to optimize dilutions for each specific experimental system to obtain optimal results . Published literature confirms successful application of EHD4 antibodies in various experimental contexts, including at least 4 publications for Western blotting and 1 publication for immunohistochemistry .

How can I verify the specificity of an EHD4 antibody?

Verifying antibody specificity is critical when studying EHD proteins due to their high homology. Multiple approaches should be employed:

• Immunoblotting comparison: Test the antibody against lysates from cells expressing each EHD family member (EHD1-4). A specific EHD4 antibody should exclusively recognize EHD4 and not cross-react with other EHD proteins .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before immunoblotting or immunostaining. This should abolish detection if the antibody is specific .

• siRNA/shRNA knockdown validation: Deplete EHD4 using RNA interference and confirm reduced signal in immunoblotting or immunostaining experiments .

• Immunoprecipitation specificity: Perform immunoprecipitation from cells expressing all EHD proteins and verify that only EHD4 is pulled down, as demonstrated with antibodies used in published studies .

• Knockout validation: If available, tissues or cells from EHD4 knockout animals provide definitive validation—the antibody should produce no signal in these samples .

How can EHD4 antibodies be used to study endosomal trafficking pathways?

EHD4 antibodies are powerful tools for investigating endosomal trafficking pathways through multiple experimental approaches:

• Colocalization studies: Immunofluorescence microscopy using EHD4 antibodies in combination with markers for distinct endosomal compartments (such as Rab5, EEA1 for early endosomes; Rab11 for recycling endosomes) can reveal the subcellular distribution of EHD4. Research has demonstrated significant colocalization of EHD4 with early endosomal markers, indicating its role in early endocytic trafficking .

• Cargo trafficking assays: Following depletion of EHD4 (via siRNA), researchers can track the trafficking of endocytic cargo such as major histocompatibility complex class I (MHCI) proteins. Studies have shown that EHD4 knockdown causes retention of cargo in enlarged early endosomes, suggesting its role in facilitating cargo exit from this compartment .

• Live-cell imaging: When combined with fluorescently tagged cargo proteins, EHD4 antibodies can be used in fixed-cell timepoint experiments to track the dynamic regulation of endosomal transport.

• Morphological analysis: EHD4 antibodies enable assessment of endosomal morphology alterations resulting from EHD4 manipulation. Research has demonstrated that EHD4 depletion leads to enlarged early endosomal structures, providing insights into its functional role .

What are the optimal conditions for detecting EHD4 in different tissue types using immunohistochemistry?

Optimal detection of EHD4 in tissue sections requires careful consideration of fixation, antigen retrieval, and antibody incubation conditions:

• Fixation: Standard formalin fixation and paraffin embedding protocols are generally suitable.

• Antigen retrieval: Heat-induced epitope retrieval using TE buffer at pH 9.0 is suggested as the primary method. Alternatively, citrate buffer at pH 6.0 may be used if the primary method yields suboptimal results .

• Antibody dilution: For immunohistochemical applications, a dilution range of 1:50-1:500 is recommended, with the specific optimal dilution depending on the tissue type and detection system used .

• Detection system: Standard secondary antibody detection systems (such as HRP-conjugated or fluorescently labeled secondary antibodies) are appropriate.

• Tissue expression considerations: EHD4 expression has been documented in various tissues including lung, kidney, heart, spleen, brain, thymus, and testis, with varying expression levels. Liver tissues may require longer exposure times or more concentrated antibody solutions due to lower expression levels .

How can I troubleshoot weak or non-specific EHD4 antibody signals in Western blotting?

When encountering weak or non-specific signals in Western blotting with EHD4 antibodies, consider the following troubleshooting approaches:

• Sample preparation optimization:

  • Ensure complete cell/tissue lysis using appropriate buffers containing protease inhibitors

  • Optimize protein loading (typically 20-50 μg of total protein)

  • Verify protein transfer efficiency using Ponceau S staining

• Antibody dilution adjustment:

  • For weak signals: Increase antibody concentration (use lower dilutions within the 1:1000-1:8000 recommended range)

  • For non-specific bands: Increase dilution and optimize blocking conditions

• Blocking optimization:

  • Test different blocking agents (BSA vs. non-fat milk)

  • Extend blocking time to reduce background

  • Include 0.1% Tween-20 in wash and antibody dilution buffers

• Detection system sensitivity:

  • Use enhanced chemiluminescence (ECL) substrates with appropriate sensitivity

  • Adjust exposure times based on expression levels (e.g., longer exposures may be needed for liver samples)

• Specificity confirmation:

  • Include positive controls (e.g., HEK-293T, HepG2, or A431 cells known to express EHD4)

  • Run peptide competition controls

  • Consider including EHD4-depleted samples as negative controls

How should researchers design experiments to distinguish between EHD4 and other EHD family members?

Designing experiments to specifically study EHD4 while accounting for potential functional overlap with other EHD family members requires careful consideration:

• Antibody selection: Use antibodies raised against unique sequences of EHD4 not present in other EHD proteins. Published studies have utilized antibodies targeting a unique C-terminal sequence of EHD4 that shows high specificity .

• Expression analysis controls: When analyzing EHD4 expression, include controls examining other EHD family members to account for potential compensatory expression changes. Studies have shown that knockdown of EHD4 can lead to upregulation of other EHD proteins (e.g., increased EHD2 in lungs and EHD1 in heart tissue of EHD4-null mice) .

• siRNA/shRNA design: Design silencing RNAs targeting unique sequences of EHD4 and validate knockdown specificity by demonstrating no effect on other EHD protein levels .

• Rescue experiments: For functional studies, include rescue experiments with siRNA-resistant EHD4 constructs to confirm phenotype specificity .

• Domain-specific mutation approaches: Use targeted mutations in EHD4-specific domains to dissect functional differences from other family members.

What considerations are important when using EHD4 antibodies for studies of endocytic trafficking?

When investigating endocytic trafficking pathways using EHD4 antibodies, researchers should consider:

• Pathway specificity: EHD4 participates in both clathrin-dependent and clathrin-independent endocytic pathways. Experimental designs should account for this by including appropriate cargo markers for each pathway (e.g., transferrin for clathrin-dependent and MHCI for clathrin-independent pathways) .

• Temporal dynamics: Endocytic trafficking occurs with precise timing. Design pulse-chase experiments with appropriate time points (e.g., 20 minutes for early endosome localization, 40+ minutes for recycling endosome trafficking) to capture the dynamic nature of EHD4's role .

• Subcellular marker selection: Include multiple endosomal compartment markers (e.g., Rab5 and EEA1 for early endosomes, Rab11 for recycling endosomes) to precisely map EHD4's involvement in specific trafficking steps .

• Morphological analysis parameters: When assessing the impact of EHD4 manipulation on endosomal morphology, establish quantitative metrics (size, number, distribution) for objective comparison between experimental conditions .

• Technical controls for immunofluorescence: Include antibody specificity controls and single-staining controls to rule out fluorescence channel bleed-through when performing colocalization studies.

How can EHD4 antibodies be utilized in studies involving knockout or transgenic animal models?

EHD4 antibodies serve multiple critical functions in studies using knockout or transgenic animal models:

• Knockout validation: Antibodies provide essential validation of complete protein depletion in knockout models. Western blotting of multiple tissues from wild-type, heterozygous, and knockout animals can confirm the absence of full-length or truncated EHD4 protein products .

• Compensatory mechanism assessment: EHD4 antibodies can be used alongside antibodies against other EHD family members to evaluate compensatory expression changes in knockout models. For example, studies have demonstrated increased EHD2 levels in lungs and EHD1 levels in hearts of EHD4-knockout mice .

• Tissue-specific expression profiling: Immunohistochemistry with EHD4 antibodies can characterize tissue distribution patterns in wild-type animals to guide phenotypic analysis of knockout models. Published research detected EHD4 expression in multiple tissues including lung, kidney, heart, spleen, brain, thymus, and testis, with variable expression levels .

• Phenotype correlation studies: Correlating the degree of phenotypic abnormality with EHD4 expression levels in heterozygous versus homozygous knockout animals can provide insights into dose-dependent functions.

• Developmental expression analysis: Immunostaining of tissues at different developmental stages can reveal temporal aspects of EHD4 function, particularly important for developmental phenotypes like the pre-pubertal testis size defects observed in EHD4-knockout mice .

How should researchers interpret altered EHD4 localization patterns in disease models?

Interpreting changes in EHD4 localization patterns in disease models requires a systematic analytical approach:

• Baseline establishment: First establish normal EHD4 localization patterns in relevant cell types or tissues. In healthy cells, EHD4 typically exhibits a punctate distribution with occasional tubular structures, and significantly colocalizes with early endosomal markers like Rab5 and EEA1 .

• Quantitative analysis: Employ quantitative colocalization metrics (Pearson's correlation coefficient, Mander's overlap coefficient) to objectively measure changes in EHD4 association with specific endosomal compartments in disease contexts.

• Context-specific considerations: Interpret localization changes within the context of known endocytic trafficking alterations in the specific disease. For example, in conditions characterized by enlarged endosomes, changes in EHD4 distribution may represent a compensatory response rather than a causative mechanism.

• Functional correlation: Correlate localization changes with functional endocytic pathway alterations. For instance, dissociation of EHD4 from early endosomes may correlate with impaired cargo sorting or delayed endosomal maturation.

• Integration with other EHD family data: Consider alterations in localization patterns of other EHD family members, as there may be compensatory redistribution among family members in disease states.

What are the implications of altered EHD4 expression levels in different experimental systems?

Changes in EHD4 expression levels can have various implications depending on the experimental context:

• Upregulation scenarios: Increased EHD4 expression may represent compensatory responses to endocytic trafficking defects. Elevated levels could potentially accelerate cargo transport through early endosomes or alter sorting decisions between recycling and degradative pathways.

• Downregulation scenarios: Decreased EHD4 expression, either experimentally induced or disease-associated, typically results in enlarged early endosomes and impaired cargo trafficking from these compartments to both recycling and late endocytic pathways .

• Cell-type specific considerations: The impact of altered EHD4 expression may vary significantly between cell types due to differential expression of other trafficking regulators and compensatory mechanisms. For example, tissues showing upregulation of other EHD proteins in response to EHD4 depletion may exhibit less severe trafficking defects .

• Temporal aspects: Acute versus chronic changes in EHD4 expression may have different consequences due to compensatory adaptations over time. Transient siRNA-mediated knockdown may produce more pronounced phenotypes than observed in knockout animal models where developmental compensation occurs.

• Threshold effects: Partial reduction in EHD4 levels may have minimal functional impact in some systems, as suggested by the relatively normal expression of EHD4 at approximately half the wild-type level in heterozygous animals .

How can EHD4 antibodies be combined with other techniques to study protein-protein interactions?

EHD4 antibodies can be integrated with multiple techniques to investigate protein-protein interactions:

• Co-immunoprecipitation (Co-IP): EHD4 antibodies can be used to pull down EHD4 protein complexes from cell or tissue lysates, followed by immunoblotting for suspected interacting partners. This approach has been validated for studying EHD4-specific interactions .

• Proximity ligation assay (PLA): This technique combines EHD4 antibodies with antibodies against potential interaction partners to detect proteins residing within 40 nm of each other in fixed cells, providing in situ evidence of protein proximity.

• Immunofluorescence colocalization: Dual immunostaining with EHD4 antibodies and antibodies against potential interacting proteins can provide spatial information about their relationship in cellular compartments. This approach has been successfully used to demonstrate EHD4 colocalization with early endosomal markers Rab5 and EEA1 .

• Pull-down assays with domain mutants: Combining EHD4 antibodies with expression of domain-specific EHD4 mutants can help map interaction interfaces. For example, mutations in the EH domain might disrupt specific protein interactions that can be detected by comparative Co-IP.

• Cross-linking mass spectrometry: Chemical cross-linking of protein complexes followed by immunoprecipitation with EHD4 antibodies and mass spectrometry analysis can identify both direct and indirect interaction partners in native cellular contexts.

What are the methodological considerations for studying EHD4 in tissues with low endogenous expression?

Studying EHD4 in tissues with low expression levels presents specific challenges requiring methodological adaptations:

• Signal amplification strategies:

  • Use high-sensitivity detection systems for Western blotting (enhanced chemiluminescent substrates)

  • Consider tyramide signal amplification for immunohistochemistry applications

  • Extend exposure times during imaging/development (as noted for liver tissue detection)

• Sample enrichment approaches:

  • Increase protein loading amounts for Western blotting

  • Consider subcellular fractionation to concentrate early endosomal fractions where EHD4 is enriched

  • Use immunoprecipitation to concentrate EHD4 before detection

• Antibody optimization:

  • Test multiple anti-EHD4 antibodies targeting different epitopes

  • Use lower dilutions within the recommended range (e.g., 1:50-1:100 for IHC)

  • Optimize antigen retrieval conditions (TE buffer pH 9.0 is recommended, but citrate buffer pH 6.0 may be tested as an alternative)

• Controls and validation:

  • Include positive control tissues with known high EHD4 expression (e.g., kidney, testis)

  • Use tissues from EHD4 knockout animals as definitive negative controls

  • Consider parallel analysis with mRNA detection methods (RT-PCR, in situ hybridization) to confirm expression patterns

How can researchers investigate the functional relationship between EHD4 and other endosomal trafficking proteins?

Investigating functional relationships between EHD4 and other trafficking regulators requires multi-faceted experimental approaches:

• Sequential and simultaneous depletion: Compare phenotypes resulting from individual versus combined knockdown of EHD4 and interacting partners. Additive, synergistic, or rescue effects can reveal functional relationships. For example, knockdown of EHD4 along with other early endosomal regulators can determine whether they function in the same or parallel pathways.

• Rescue experiments with mutant constructs: Express siRNA-resistant wild-type or mutant EHD4 in depleted cells to determine which domains are required for functional complementation . This approach can reveal whether specific protein interactions are essential for EHD4 function.

• Cargo trafficking assays: Track the movement of model cargo (e.g., MHCI, transferrin) in cells with manipulated levels of EHD4 and other trafficking regulators . Quantitative analysis of trafficking kinetics can reveal rate-limiting steps and regulatory hierarchies.

• Dominant-negative approaches: Overexpress functionally impaired EHD4 mutants to disrupt specific protein interactions or functions, then assess the impact on other trafficking components through localization studies and functional assays.

• Correlative live-cell and immunoelectron microscopy: Combine dynamic visualization of fluorescently tagged trafficking components with ultrastructural localization of endogenous EHD4 using specific antibodies to precisely map functional relationships at the ultrastructural level.